Clinical Trial

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Name: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers — clinical trial record (NCT05891171)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ARC-25

Active, Not Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Protocol Amendment History 2 changes

notable Primary completion pushed: 2026-03 -> 2027-09 2026-06-06

minor Completion pushed: 2026-03 -> 2027-09 2026-06-06

Trial Details

NCT Number	NCT05891171
Lead Sponsor	Arcus Biosciences, Inc.
Conditions	Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC) +4 more
Enrollment	40 participants
Start Date	2023-10-13
Primary Completion	2027-09 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-30